drugset / Trial / NCT00942526

Oral Anti-Infective Agent for Esophageal Anastomotic Leakage

NCT00942526 ↗

Phase 2 Unknown 120 enrolled National Taiwan University Hospital
RandomizedFactorialOpen-labelTreatment

Summary

Anastomotic leakage is still to be a major cause of considerable morbidity and mortality after esophagectomy and gastric pull up for esophageal carcinoma. Risk factor analyses of anastomotic leakage, including blood supply, graft tension, and comorbidity, have been performed, but few studies have produced strategies that have improved operative results. This study will be performed to identify prognostic variables that might be used to develop a strategy for optimizing outcomes after esophagogastrectomy.

Timeline

Start
2009-06
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycostatin oral suspension Unknown 5 ml Oral

Indications

No indication recorded.